\-\ Texto\\:\\ \ \(0\)\
\-\ vs\\:\\ bp\\ 108\\-126\\/64\\-78\\ \\ rr\\ 20\\-24\\ hr\\ 114\\-170\\ t\\ 36\\.7\\-38\\.8\\ wt\\ 18\\.35kg\\ \ \(0\)\
\-\ gen\\:\\ thin\\ female\\.\\ yelling\\/crying\\ on\\ initial\\ exam\\ with\\ intermittent\\ calm\\ episodes\\.\\ distressed\\ in\\ appearance\\ and\\ not\\ smiling\\.\\ \ \(0\)\
\-\ heent\\:\\ nc\\/at\\.\\ eomi\\.\\ perrl\\.\\ glassy\\ sclera\\,\\ no\\ conjunctivitis\\.\\ no\\ eye\\ discharge\\.\\ tms\\ clear\\ bilaterally\\ and\\ well\\-visulaized\\.\\ no\\ tonsilar\\ exudate\\ with\\ some\\ erythema\\.\\ strawberry\\ tongue\\.\\ dry\\/cracked\\ lips\\.\\ no\\ rhinorrhea\\.\\ \ \(0\)\
\-\ neck\\:\\ supple\\,\\ no\\ lymphadenopathy\\.\\ no\\ rigidity\\.\\ \ \(0\)\
\-\ pulm\\:\\ ctab\\.\\ good\\ air\\ entry\\.\\ no\\ wheeze\\/rhonchi\\/rales\\.\\ \ \(0\)\
\-\ cv\\:\\ rrr\\,\\ nomral\\ s1\\/s2\\.\\ no\\ murmur\\.\\ 2\\+\\ pulses\\.\\ cr\\ \\<\\ 2sec\\.\\ \ \(0\)\
\-\ abd\\:\\ soft\\,\\ nd\\.\\ \\+bs\\,\\ no\\ masses\\ or\\ hsm\\.\\ no\\ palpable\\ bladder\\ edge\\.\\ \\ crying\\ throughout\\ exam\\ and\\ unable\\ to\\ localize\\ pain\\.\\ \ \(0\)\
\-\ gu\\:\\ \\ tanner\\ 1\\ female\\.\\ minimal\\ erythema\\ at\\ opening\\ of\\ vagina\\ with\\ normal\\ labia\\.\\ no\\ lesions\\.\\ \ \(0\)\
\-\ ext\\/msk\\:\\ from\\ all\\ extremities\\.\\ no\\ edmea\\.\\ crying\\ with\\ palpation\\ of\\ all\\ extremities\\,\\ pale\\ but\\ not\\ cool\\.\\ \ \(0\)\
\-\ neuro\\:\\ unable\\ to\\ complete\\ exam\\ with\\ poor\\ cooperation\\.\\ extremely\\ hypersensative\\ to\\ touch\\.\\ responds\\ normally\\ to\\ parents\\.\\ tone\\ and\\ strength\\ seem\\ appropriate\\.\\ not\\ able\\ to\\ check\\ stance\\/gait\\.\\ \ \(0\)\
\-\ derm\\:\\ fine\\,\\ pink\\,\\ sandpaper\\ type\\ rash\\ on\\ back\\ and\\ upper\\ extremities\\.\\ \ \(0\)\
\-\ admit\\ labs\\:\\ \ \(0\)\
\-\ wbc\\:\\ 32\\.4\\ h\\/h\\ 11\\.2\\/34\\ platelet\\ 654\\ \\ diff\\.\\ 1\\ band\\ 92\\ segs\\ 5\\ lymph\\ 2\\ mono\\ anc\\ 30\\.13\\ \ \(0\)\
\-\ ua\\ cath\\ specimen\\:\\ ph\\ 7\\.5\\,\\ specific\\ gravity\\ 1\\.016\\,\\ otherwise\\ negative\\ \ \(0\)\
\-\ na\\ 135\\ k\\ 3\\.9\\ cl\\ 99\\ co2\\ 23\\.6\\ glucose\\ 99\\ bun\\ 6\\ cr\\ 0\\.4\\ \ \(0\)\
\-\ urin\\ culture\\:\\ \\>\\ 100\\,000\\ col\\/ml\\ enterococcus\\ \\(group\\ d\\ strep\\)\\ \ \(0\)\
\-\ crp\\ 3\\.35\\ \ \(0\)\
\-\ esr\\ 66\\ \ \(0\)\
\-\ ldh\\ 153\\ \ \(0\)\
\-\ hepatic\\ function\\:\\ albumin\\ 3\\.4\\,\\ alk\\ phos\\ 199\\,\\ tbili\\ 0\\.2\\,\\ dbili\\ 0\\.0\\,\\ ibili\\ 0\\.2\\,\\ ast\\ 14\\,\\ alt\\ 20\\,\\ tprotein\\ 7\\.5\\,\\ amylase\\ 34\\,\\ lipase\\ 305\\ \ \(0\)\
\-\ csf\\:\\ glucose\\ 48\\,\\ protein\\ 57\\.6\\,\\ neutrophil\\ 43\\,\\ lymphocyte\\ 23\\,\\ monocyte\\/macrophage\\ 34\\,\\ wbc\\ 245\\,\\ rbc\\ 8\\ \ \(0\)\
\-\ ferretin\\ 155\\ \ \(0\)\
\-\ normal\\ studies\\:\\ blood\\ culture\\,\\ rapid\\ strep\\ and\\ throat\\ culture\\,\\ csf\\ culture\\,\\ spinal\\ fluid\\ analysis\\,\\ ana\\,\\ rf\\,\\ cmv\\ titers\\,\\ ebv\\ titers\\,\\ hiv\\,\\ rpr\\,\\ borrelia\\ burgdorferi\\ abs\\,\\ mycoplasma\\ p\\.\\ igg\\ \\&\\ igm\\,\\ acute\\ leukemia\\ profile\\,\\ aso\\ titer\\,\\ anti\\-dnase\\ b\\,\\ multiple\\ sclerosis\\ panel\\ 2\\,\\ triglyceride\\,\\ fibrinogen\\,\\ total\\ ck\\,\\ uric\\ acid\\.\ \(0\)\
\-\ multiple\\ sclerosis\\ panel2\\:\\ oligoclonal\\ banding\\ csf\\ pending\\.\\ \\ myelin\\ basic\\ protein\\ 5\\.1\\ \\(reference\\ range\\ 4\\.1\\-6\\.0\\ weakly\\ positive\\)\\.\\ \\ albumin\\ 4\\.8\\.\\ albumin\\ csf\\ 30\\.8\\.\\ igg\\ csf\\ 2\\.5\\.\\ immunoglobulin\\ g\\ 699\\.\\ igg\\ synthesis\\ rate\\ 0\\.2\\ \\(neg\\)\\.\\ igg\\ index\\ 0\\.55\ \(0\)\
\-\ consult\\ services\\:\\ id\\,\\ neurology\\,\\ rheumatology\\,\\ heme\\/onc\\,\\ opthamology\\,\\ urology\\.\\ \ \(0\)\
\-\ patient\\ was\\ admitted\\ to\\ the\\ general\\ medical\\ floor\\ for\\ evaluation\\ and\\ management\\.\\ there\\ was\\ initial\\ concern\\ for\\ an\\ infectious\\ etiology\\ with\\ the\\ patient\\‚\\Ä\\ôs\\ history\\ of\\ fevers\\ and\\ confusion\\.\\ \\ serial\\ blood\\ cultures\\ were\\ all\\ no\\ growth\\.\\ \\ the\\ patient\\ was\\ empirically\\ started\\ on\\ vancomycin\\,\\ rocephin\\ and\\ acyclovir\\.\\ initial\\ positive\\ urin\\ culture\\ was\\ thought\\ to\\ have\\ been\\ secondary\\ to\\ repeated\\ catherizations\\.\\ \\ acyclrovir\\ was\\ stopped\\ once\\ hsv\\ pcr\\ was\\ negative\\,\\ and\\ the\\ rest\\ of\\ antibiotic\\ regimen\\ was\\ completed\\ for\\ a\\ ten\\ day\\ course\\.\\ this\\ was\\ not\\ thought\\ to\\ be\\ an\\ infectious\\ process\\ after\\ review\\ of\\ the\\ laboratory\\ study\\ results\\.\\ \\ no\\ noted\\ masses\\ on\\ imaging\\,\\ a\\ normal\\ bone\\ scan\\,\\ and\\ a\\ normal\\ bone\\ marrow\\ aspirate\\ analysis\\ made\\ the\\ concern\\ for\\ malignancy\\ less\\ likely\\.\\ \\ presenting\\ complaint\\ of\\ diffuse\\ pain\\ and\\ fever\\ with\\ strong\\ family\\ history\\ of\\ autoimmune\\ disease\\ raised\\ concern\\ for\\ a\\ possible\\ rheumatologic\\ disorder\\ such\\ as\\ jia\\ or\\ sle\\.\\ with\\ laboratory\\ evaluation\\,\\ the\\ consulting\\ rheumatologist\\ thought\\ that\\ the\\ patient\\‚\\Ä\\ôs\\ presentation\\ was\\ more\\ consistent\\ with\\ a\\ possible\\ vasculitis\\.\\ \ \(0\)\
\-\ on\\ further\\ neurological\\ examination\\,\\ the\\ patient\\ was\\ noted\\ to\\ have\\ bilateral\\ clonus\\ and\\ weakness\\ of\\ the\\ lower\\ extremities\\.\\ she\\ received\\ three\\ days\\ of\\ high\\ dose\\ steroid\\ therapy\\ after\\ which\\ she\\ had\\ remarkable\\ improvement\\ in\\ her\\ symptoms\\.\\ \\ she\\ was\\ ddischarged\\ home\\ after\\ a\\ ten\\ day\\ hospitalization\\ with\\ out\\-patient\\ follow\\-up\\ with\\ neurology\\ and\\ rheumatology\\ with\\ the\\ diagnosis\\ of\\ transverse\\ mellitus\\.\ \(0\)\
\-\ however\\,\\ she\\ returned\\ to\\ the\\ ed\\ just\\ five\\ days\\ after\\ her\\ discharge\\ home\\ and\\ was\\ readmitted\\ to\\ the\\ hospital\\ for\\ recurrence\\ of\\ symptoms\\ that\\ included\\:\\ head\\ ache\\,\\ urinary\\ retention\\,\\ change\\ in\\ mental\\ status\\/confusion\\,\\ and\\ difficulty\\ with\\ ambulation\\,\\ fever\\ and\\ left\\ eye\\ drifting\\.\\ further\\ laboratory\\ and\\ imaging\\ studies\\ were\\ obtained\\ and\\ no\\ infectious\\ cause\\ identified\\.\\ \\ preliminary\\ diagnoses\\ of\\ transverse\\ meylitis\\ from\\ the\\ first\\ hospital\\ admit\\ was\\ reconsidered\\.\\ during\\ her\\ second\\ admission\\,\\ she\\ received\\ five\\ days\\ of\\ iv\\ steroid\\ therapy\\.\\ \\ she\\ had\\ resolution\\ of\\ her\\ symptoms\\ and\\ was\\ discharged\\ home\\ on\\ continued\\ oral\\ steroid\\ therapy\\.\\ \\ final\\ diagnosis\\ upon\\ discharge\\ home\\ with\\ consideration\\ of\\ laboratory\\ and\\ imaging\\ evaluation\\ and\\ consulting\\ expertise\\ was\\ adem\\.\ \(0\)\
\-\ 4\\/20\\ mri\\ c\\/t\\/l\\ w\\/o\\ \\&\\ w\\ cntr\\:\\ \\ impression\\:\\ suggestion\\ of\\ very\\ subtle\\/mild\\ t2\\ prolongation\\ in\\ the\\ central\\ white\\ matter\\ of\\ the\\ cord\\ from\\ about\\ c4\\-t2\\.\\ this\\ could\\ potentially\\ represent\\ early\\/mild\\ transverse\\ myelitis\\.\\ \ \(0\)\
\-\ 4\\/20\\ mri\\ brain\\ w\\/o\\ \\&\\ w\\,\\ cow\\ mra\\:\\ impression\\:\\ 1\\.\\ the\\ mild\\ t2\\ prolongation\\ in\\ the\\ cerebral\\ sulci\\ described\\ on\\ yesterday\\'s\\ exam\\ is\\ again\\ seen\\ on\\ the\\ axial\\ flair\\ images\\,\\ however\\ this\\ finding\\ is\\ seen\\ fairly\\ frequently\\ in\\ patient\\'s\\ receiving\\ supplemental\\ oxygen\\ during\\ brain\\ mri\\ and\\ is\\ likely\\ not\\ clinically\\ significant\\.\\ 2\\.\\ pineal\\ cyst\\.\\ 3\\.\\ otherwise\\ normal\\ study\\.\\ \\ \\ \ \(0\)\
\-\ nuc\\ bone\\ scan\\ whole\\ body\\ ecg\\ and\\ echo\\:\\ \\ normal\\ study\\ \ \(0\)\
\-\ 4\\/28\\ mri\\ brain\\ w\\/\\ \\&\\ w\\/o\\ contrast\\:\\ \\ impression\\:\\ questionable\\ area\\ of\\ increased\\ signal\\ at\\ the\\ body\\ of\\ the\\ corpus\\ callosum\\ is\\ felt\\ to\\ represent\\ volume\\ averaging\\ of\\ adjacent\\ cortical\\ gray\\ matter\\.\\ the\\ brain\\ has\\ a\\ normal\\ appearance\\ without\\ evidence\\ of\\ breakdown\\ of\\ the\\ blood\\-brain\\ barrier\\.\\ \ \(0\)\
\-\ 5\\/4\\ mri\\ brain\\ w\\/\\ and\\ w\\/o\\ contrast\\:\\ impression\\:\\ small\\ patchy\\ areas\\ of\\ t2\\ prolongation\\ are\\ now\\ demonstrated\\ in\\ the\\ white\\ matter\\ of\\ the\\ cerebral\\ hemispheres\\,\\ right\\ corpus\\ callosum\\,\\ right\\ cerebral\\ peduncle\\,\\ and\\ middle\\ cerebellar\\ peduncles\\ bilaterally\\.\\ given\\ the\\ patient\\'s\\ clinical\\ history\\,\\ this\\ may\\ represent\\ acute\\ disseminated\\ encephalomyelitis\\ \\(adem\\)\\.\\ although\\ less\\ likely\\,\\ the\\ differential\\ diagnosis\\ would\\ also\\ include\\ childhood\\ onset\\ of\\ multiple\\ sclerosis\\.\\ \ \(0\)\
\-\ 5\\/5\\ ir\\ angio\\ carotid\\ cerebral\\ bilat\\ sel\\:\\ normal\\ cerebral\\ angiogram\\.\ \(0\)\
\-\ acute\\ disseminated\\ encephalomyelitis\ \(7\)\
\-\ \\‚\\Ä\\¢\\ multiple\\ sclerosis\\ \\(ms\\)\ \(0\)\
\-\ \\‚\\Ä\\¢\\ acute\\ disseminated\\ encephalomyelitis\\ \\(adem\\)\\ \ \(0\)\
\-\ \\‚\\Ä\\¢\\ acute\\ hemorrhagic\\ encephalomyelitis\\ \ \(0\)\
\-\ \\‚\\Ä\\¢\\ progressive\\ multifocal\\ leukoencephalitis\\ \\(pml\\)\ \(0\)\
\-\ \\‚\\Ä\\¢\\ subacute\\ sclerosing\\ panencephalitis\\ \ \(0\)\
\-\ \\‚\\Ä\\¢\\ collagen\\ vascular\\ disease\\ \ \(1\)\
\-\ \\‚\\Ä\\¢\\ optic\\ neuritis\\ \ \(0\)\
\-\ \\‚\\Ä\\¢\\ transverse\\ myelitis\\ \ \(0\)\
\-\ \\‚\\Ä\\¢\\ neuromyelitis\\ optica\\ \\(devic\\‚\\Ä\\ôs\\ disease\\)\\ \ \(0\)\
\-\ \\‚\\Ä\\¢\\ acute\\ inflammatory\\ demyelinating\\ polyneuropathy\\ \\(aidp\\,\\ guillain\\-barre\\ syndrome\\)\ \(0\)\
\-\ 4\\ y\\/o\\ previously\\ healthy\\ girl\\ presentsto\\ the\\ ed\\ with\\ a\\ two\\ week\\ history\\ of\\ fever\\,\\ pna\\ for\\ which\\ she\\ was\\ treated\\ with\\ two\\ courses\\ of\\ antibiotics\\,\\ worsening\\ abdominal\\ pain\\,\\ urinary\\ retention\\ and\\ increased\\ difficulty\\ with\\ ambulation\\.\\ \\ during\\ this\\ two\\ week\\ time\\ frame\\,\\ she\\ had\\ a\\ bowel\\ clean\\ out\\ and\\ required\\ three\\ straight\\ catheterizations\\ for\\ urinary\\ retention\\.\\ \\ she\\ had\\ been\\ seen\\ by\\ her\\ primary\\ care\\ provider\\ and\\ in\\ the\\ ed\\ with\\ treatment\\ for\\ presumed\\ pna\\,\\ constipation\\,\\ and\\ urinary\\ retention\\ on\\ several\\ occurrences\\ over\\ these\\ past\\ two\\ weeks\\.\\ \\ parents\\ expressed\\ concern\\ for\\ weight\\ loss\\ of\\ approximately\\ three\\ pounds\\ during\\ this\\ time\\ frame\\.\\ \\ the\\ mother\\ also\\ reported\\ that\\ the\\ patient\\ seemed\\ very\\ sensitive\\ to\\ touch\\ and\\ movement\\ as\\ if\\ \\‚\\Ä\\úeverything\\ hurt\\ her\\‚\\Ä\\ù\\ over\\ the\\ preceding\\ days\\ to\\ her\\ admission\\.\ \(0\)\
\-\ this\\ patient\\‚\\Ä\\ôs\\ initial\\ presentation\\ was\\ concerning\\ for\\ autoimmune\\ and\\/or\\ infectious\\ etiology\\ affecting\\ her\\ central\\ nervous\\ system\\.\\ \\ preliminary\\ diagnosis\\ of\\ acute\\ transverse\\ myelitis\\,\\ sometimes\\ refered\\ to\\ as\\ acute\\ transverse\\ myelopathy\\,\\ \\ is\\ characterized\\ by\\ an\\ acutely\\ developing\\,\\ rapidly\\ progressing\\ lesion\\ affecting\\ the\\ spinal\\ cord\\.\\ \\ onset\\ of\\ disease\\ may\\ occur\\ during\\ active\\ infection\\ or\\ as\\ a\\ post\\-infectious\\ demyelinating\\ disorder\\.\\ \\ cases\\ have\\ also\\ been\\ reported\\ post\\-vaccination\\,\\ autoimmune\\ or\\ as\\ systemic\\ malignancy\\.\\ \\ any\\ segment\\ of\\ the\\ spinal\\ column\\ may\\ be\\ affected\\,\\ although\\ there\\ is\\ increased\\ predominance\\ for\\ the\\ thoracic\\ cord\\ with\\ multilevel\\ involvement\\ common\\.\\ \\ neuroimaging\\ is\\ recommended\\ for\\ evaluation\\ of\\ conditions\\ that\\ can\\ mimic\\ acute\\ transverse\\ myelitis\\:\\ acute\\ disk\\ herniation\\,\\ hematoma\\,\\ epidural\\ abscess\\,\\ or\\ compression\\ myelopathies\\.\\ \\ during\\ the\\ acute\\ phase\\,\\ mr\\ scans\\ can\\ be\\ normal\\ and\\ nonspecific\\.\\ \\ t1\\ may\\ show\\ focal\\ cord\\ enlargement\\ and\\ t2\\ with\\ poorly\\ delineated\\ hyperintensities\\ as\\ the\\ most\\ commonly\\ identified\\ abnormalities\\.\\ \ \(0\)\
\-\ with\\ the\\ presumptive\\ diagnosis\\ of\\ transverse\\ myelitis\\,\\ multiple\\ sclerosis\\ \\(ms\\)\\ was\\ also\\ considered\\.\\ \\ although\\ ms\\ is\\ considered\\ an\\ adult\\ disease\\,\\ symptoms\\ can\\ begin\\ during\\ childhood\\ \\(before\\ the\\ age\\ of\\ 5\\)\\.\\ \\ presenting\\ symptoms\\ can\\ be\\ as\\ subtle\\ as\\ school\\ problems\\ to\\ more\\ pronounced\\ with\\ paresthesias\\,\\ cerebral\\ edema\\,\\ meningismus\\ and\\ impaired\\ consciousness\\.\\ \\ mr\\ imaging\\ is\\ the\\ study\\ of\\ choice\\ in\\ diagnosis\\ of\\ ms\\ and\\ in\\ the\\ evaluation\\ of\\ disseminated\\ lesions\\.\\ \\ lesions\\ typically\\ are\\ sharply\\ marginated\\ with\\ prolongation\\ of\\ t1\\ and\\ t2\\ relaxation\\ times\\.\\ \\ t2\\-weighted\\ images\\ might\\ show\\ a\\ central\\ area\\ of\\ very\\ high\\ signal\\ intensity\\ surrounded\\ by\\ peripheral\\ area\\ of\\ moderately\\ high\\ intensity\\.\\ \\ new\\ lesions\\ generally\\ enhance\\ on\\ average\\ for\\ three\\ weeks\\.\\ \\ tumefactive\\ plaques\\ in\\ the\\ brainstem\\ and\\ spinal\\ cord\\ might\\ be\\ present\\ with\\ extensive\\ swelling\\ with\\ mr\\ signal\\ changes\\ suggestive\\ of\\ neoplasm\\.\\ \\ tumefactive\\ plaques\\ may\\ be\\ differentiated\\ from\\ tumors\\ by\\ presence\\ of\\ other\\ typical\\ plaques\\ and\\ lack\\ of\\ mass\\ effect\\.\\ \\ plaques\\ will\\ be\\ adjacent\\ to\\ ventricular\\ surface\\ and\\ enhancement\\ will\\ be\\ limited\\ to\\ one\\ side\\ of\\ the\\ lesion\\.\\ \\ \\ some\\ ms\\ lesions\\ will\\ have\\ higher\\ intensity\\ on\\ precontrast\\ t1\\-weighted\\ images\\ necessitating\\ precontrast\\ and\\ postcontrast\\ evaluation\\ if\\ magnetization\\ transfer\\ is\\ used\\.\\ \\ magnetization\\ transfer\\,\\ diffusion\\ tensor\\ imaging\\ that\\ shows\\ reduced\\ anisotropy\\ in\\ affected\\ white\\ matter\\,\\ and\\ flair\\ sequences\\ will\\ show\\ abnormalities\\ in\\ ms\\ patients\\ in\\ cases\\ where\\ mr\\ may\\ appear\\ normal\\.\\ \\ magnetization\\ transfer\\ techniques\\ are\\ also\\ helpful\\ in\\ distinguishing\\ inflammation\\ that\\ occurs\\ in\\ ms\\ from\\ demylination\\,\\ which\\ demonstrates\\ more\\ reduction\\ of\\ magnetization\\ transfer\\.\\ \\ \\ \ \(0\)\
\-\ another\\ difficult\\ distinction\\ to\\ make\\ is\\ that\\ between\\ ms\\ and\\ acute\\ disseminated\\ encephalomyelitis\\ \\(adem\\)\\.\\ \\ adem\\ has\\ also\\ been\\ referred\\ to\\ as\\ paainfectious\\ encephalomyelitis\\.\\ \\ it\\ is\\ an\\ immune\\-mediated\\ response\\ to\\ a\\ preceding\\ viral\\ infection\\,\\ vaccination\\ and\\ less\\ commonly\\ a\\ bacterial\\ infection\\ or\\ drug\\ ingestion\\.\\ \\ acute\\ demyelination\\ is\\ thought\\ to\\ be\\ caused\\ by\\ antibody\\-antigen\\ complexes\\.\\ \\ perivascular\\,\\ mostly\\ perivenular\\,\\ inflammatory\\ \\(mostly\\ mononuclear\\)\\ infiltrates\\ are\\ seen\\.\\ with\\ disease\\ resolution\\,\\ there\\ is\\ increased\\ perivascular\\ astrocytosis\\.\\ incidence\\ in\\ unknown\\ with\\ occurrence\\ seen\\ in\\ all\\ ages\\,\\ although\\,\\ most\\ cases\\ are\\ seen\\ in\\ children\\ and\\ young\\ adults\\.\\ \\ there\\ is\\ typically\\ abrupt\\ onset\\ with\\ neurologic\\ symptoms\\ evident\\ in\\ one\\ to\\ three\\ weeks\\ after\\ insult\\.\\ there\\ is\\ a\\ rapid\\ clinical\\ course\\ with\\ multifocal\\ symptoms\\ consisting\\ of\\ but\\ not\\ limited\\ to\\:\\ headache\\,\\ fever\\,\\ vomiting\\,\\ nuchal\\ rigidity\\,\\ seizures\\,\\ focal\\ neurologic\\ deficits\\,\\ coma\\ and\\ death\\.\\ some\\ patients\\ will\\ have\\ full\\ recovery\\ while\\ others\\ may\\ have\\ permanent\\ neurologic\\ impairment\\ \\(10\\-30\\%\\)\\.\\ \\ neurologic\\ findings\\ typically\\ evolve\\ and\\ resolve\\ over\\ several\\ weeks\\.\\ \\ mr\\ is\\ preferred\\ to\\ ct\\ in\\ evaluating\\ for\\ adem\\.\\ \\ multifocal\\ subcortical\\ hyperintense\\ foci\\ are\\ present\\ on\\ t2\\-weighted\\ images\\.\\ \\ the\\ disease\\ process\\ can\\ involve\\ the\\ deep\\ white\\ matter\\,\\ brainstem\\,\\ and\\ cerebellum\\.\\ \\ cortical\\ and\\ deep\\ gray\\ matter\\ may\\ be\\ involved\\,\\ although\\ to\\ a\\ lesser\\ extent\\ than\\ white\\ matter\\.\\ \\ moderate\\ to\\ large\\ areas\\ of\\ demylination\\ \\(prolonged\\ t1\\ and\\ t2\\ on\\ mr\\)\\ can\\ be\\ found\\ on\\ subcortical\\ white\\ matter\\.\\ \\ lesions\\ are\\ usually\\ bilateral\\ but\\ asymmetric\\.\\ \\ adem\\ is\\ usually\\ nonhemorrhagic\\ on\\ mr\\.\\ some\\ lesions\\ may\\ also\\ enhance\\ with\\ contrast\\ administration\\.\\ periventricular\\ white\\ matter\\ is\\ involved\\ in\\ half\\ of\\ patients\\ with\\ adem\\,\\ whereas\\,\\ 90\\%\\ involvement\\ may\\ be\\ seen\\ in\\ ms\\.\\ \\ the\\ corpus\\ callosum\\ is\\ more\\ commonly\\ involved\\ in\\ ms\\ than\\ adem\\.\\ \\ mr\\ may\\ demonstrate\\ abnormalities\\ of\\ the\\ deep\\ cerebral\\ nuclei\\ in\\ as\\ many\\ as\\ 50\\%\\ of\\ pediatric\\ patients\\.\\ \\ \ \(0\)\
\-\ in\\ differentiation\\ adem\\ from\\ vasculitis\\,\\ diffusion\\ images\\ show\\ increased\\ water\\ motion\\ in\\ the\\ foci\\ of\\ demyelination\\ in\\ the\\ acute\\ and\\ subacute\\ phase\\ of\\ adem\\.\\ \\ lesions\\ from\\ vasculitis\\ show\\ reduced\\ diffusion\\ in\\ the\\ acute\\ phase\\.\\ \\ in\\ adem\\,\\ t2\\ changes\\ in\\ the\\ brain\\ evolve\\ with\\ time\\ and\\ typically\\ correlate\\ to\\ the\\ clinical\\ symptoms\\.\\ \\ follow\\-up\\ mr\\ studies\\ may\\ show\\ worsening\\ as\\ clinical\\ symptoms\\ begin\\ to\\ improve\\.\\ \\ with\\ concern\\ for\\ vasculitis\\,\\ vascular\\ imaging\\ may\\ illustrate\\ vasculitis\\ or\\ venous\\ occlusion\\ and\\ focal\\ infarcts\\.\\ \ \(0\)\
\-\ there\\ are\\ a\\ number\\ of\\ disorders\\ that\\ may\\ present\\ with\\ acute\\ neurologic\\ findings\\ similar\\ to\\ our\\ patient\\ and\\ should\\ be\\ considered\\ in\\ the\\ differential\\ during\\ the\\ evaluation\\ and\\ management\\.\\ \\ etiology\\ may\\ be\\ infectious\\,\\ autoimmune\\/immunologic\\,\\ traumatic\\,\\ or\\ oncologic\\.\\ \\ thorough\\ and\\ appropriate\\ laboratory\\ and\\ imaging\\ evaluation\\ will\\ guide\\ medical\\ diagnosis\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ adem\\:\\ 0\\.21498973884070255\ \(0\)\
\-\ and\\:\\ 0\\.19646963197228298\ \(0\)\
\-\ the\\:\\ 0\\.17973242306334858\ \(0\)\
\-\ of\\:\\ 0\\.17300863091134847\ \(0\)\
\-\ ms\\:\\ 0\\.1619701924148636\ \(0\)\
\-\ acute\\:\\ 0\\.144376813432433\ \(0\)\
\-\ in\\:\\ 0\\.1327867058015557\ \(0\)\
\-\ to\\:\\ 0\\.12927340467533466\ \(0\)\
\-\ may\\:\\ 0\\.12591283479063736\ \(0\)\
\-\ encephalomyelitis\\:\\ 0\\.11720404819828935\ \(0\)\
\-\ matter\\:\\ 0\\.11430773761095386\ \(0\)\
\-\ with\\:\\ 0\\.11105298339473847\ \(0\)\
\-\ magnetization\\:\\ 0\\.10670345360510211\ \(0\)\
\-\ was\\:\\ 0\\.10464019058294886\ \(0\)\
\-\ transverse\\:\\ 0\\.10281715208751561\ \(0\)\
\-\ myelitis\\:\\ 0\\.10046343694412153\ \(0\)\
\-\ mr\\:\\ 0\\.09713780443033482\ \(0\)\
\-\ t2\\:\\ 0\\.09596792585158456\ \(0\)\
\-\ be\\:\\ 0\\.0947329676785483\ \(0\)\
\-\ is\\:\\ 0\\.091361750505241\ \(0\)\
\-\ disseminated\\:\\ 0\\.09032901124465222\ \(0\)\
\-\ she\\:\\ 0\\.0893659152132094\ \(0\)\
\-\ during\\:\\ 0\\.0845234877852579\ \(0\)\
\-\ her\\:\\ 0\\.08336859300749083\ \(0\)\
\-\ transfer\\:\\ 0\\.08238083192637578\ \(0\)\
\-\ symptoms\\:\\ 0\\.08213996887944769\ \(0\)\
\-\ prolongation\\:\\ 0\\.08167172339348296\ \(0\)\
\-\ evaluation\\:\\ 0\\.08138198079523244\ \(0\)\
\-\ no\\:\\ 0\\.08136497523714961\ \(0\)\
\-\ cerebral\\:\\ 0\\.08089516610983626\ \(0\)\
\-\ for\\:\\ 0\\.0808920458047441\ \(0\)\
\-\ culture\\:\\ 0\\.08078342562112704\ \(0\)\
\-\ infectious\\:\\ 0\\.0805304374778079\ \(0\)\
\-\ as\\:\\ 0\\.08041412543562618\ \(0\)\
\-\ igg\\:\\ 0\\.0786559714439225\ \(0\)\
\-\ retention\\:\\ 0\\.0781360321321929\ \(0\)\
\-\ vasculitis\\:\\ 0\\.0774011887663025\ \(0\)\
\-\ white\\:\\ 0\\.07703757421858554\ \(0\)\
\-\ lesions\\:\\ 0\\.07663872628919484\ \(0\)\
\-\ concern\\:\\ 0\\.07647745726711318\ \(0\)\
\-\ on\\:\\ 0\\.0755672785623847\ \(0\)\
\-\ autoimmune\\:\\ 0\\.07464464663811696\ \(0\)\
\-\ brain\\:\\ 0\\.0727903646356783\ \(0\)\
\-\ normal\\:\\ 0\\.06810565036539831\ \(0\)\
\-\ plaques\\:\\ 0\\.06731717564945865\ \(0\)\
\-\ crying\\:\\ 0\\.06683302398350383\ \(0\)\
\-\ neurologic\\:\\ 0\\.06664450380902749\ \(0\)\
\-\ csf\\:\\ 0\\.06590216744307623\ \(0\)\
\-\ impression\\:\\ 0\\.06495166996216109\ \(0\)\
\-\ will\\:\\ 0\\.06441636820389943\ \(0\)\
\-\ show\\:\\ 0\\.06353525941196025\ \(0\)\
\-\ cord\\:\\ 0\\.06182321870014493\ \(0\)\
\-\ imaging\\:\\ 0\\.061363429688781154\ \(0\)\
\-\ laboratory\\:\\ 0\\.06056473168372459\ \(0\)\
\-\ diagnosis\\:\\ 0\\.06052962618333894\ \(0\)\
\-\ patient\\:\\ 0\\.0596788737554943\ \(0\)\
\-\ sclerosis\\:\\ 0\\.05940603567906117\ \(0\)\
\-\ home\\:\\ 0\\.05900968648489641\ \(0\)\
\-\ that\\:\\ 0\\.05790993596510865\ \(0\)\
\-\ urinary\\:\\ 0\\.05769828312434415\ \(0\)\
\-\ thought\\:\\ 0\\.057610005659591436\ \(0\)\
\-\ although\\:\\ 0\\.056779063882426574\ \(0\)\
\-\ albumin\\:\\ 0\\.05656853715677557\ \(0\)\
\-\ three\\:\\ 0\\.05598651219474005\ \(0\)\
\-\ seen\\:\\ 0\\.05497154231454453\ \(0\)\
\-\ also\\:\\ 0\\.05492243575765731\ \(0\)\
\-\ urin\\:\\ 0\\.053351726802551055\ \(0\)\
\-\ can\\:\\ 0\\.052520609330848206\ \(0\)\
\-\ or\\:\\ 0\\.05222586071761771\ \(0\)\
\-\ demylination\\:\\ 0\\.05098042320233733\ \(0\)\
\-\ extremities\\:\\ 0\\.05070555796065585\ \(0\)\
\-\ are\\:\\ 0\\.0506361426375801\ \(0\)\
\-\ have\\:\\ 0\\.04999715914862502\ \(0\)\
\-\ disease\\:\\ 0\\.049013376032798595\ \(0\)\
\-\ multifocal\\:\\ 0\\.04859105772445907\ \(0\)\
\-\ steroid\\:\\ 0\\.04823294549493044\ \(0\)\
\-\ pna\\:\\ 0\\.04799293397948027\ \(0\)\
\-\ spinal\\:\\ 0\\.047377234047854475\ \(0\)\
\-\ callosum\\:\\ 0\\.04713494789082443\ \(0\)\
\-\ typically\\:\\ 0\\.046839771573957426\ \(0\)\
\-\ from\\:\\ 0\\.04637370759312771\ \(0\)\
\-\ consulting\\:\\ 0\\.04602512513448589\ \(0\)\
\-\ precontrast\\:\\ 0\\.04602512513448589\ \(0\)\
\-\ corpus\\:\\ 0\\.04562195588552732\ \(0\)\
\-\ admit\\:\\ 0\\.04524418624297562\ \(0\)\
\-\ fever\\:\\ 0\\.04523856239686856\ \(0\)\
\-\ increased\\:\\ 0\\.04510029642159236\ \(0\)\
\-\ discharge\\:\\ 0\\.0448731339286541\ \(0\)\
\-\ initial\\:\\ 0\\.04475985789958854\ \(0\)\
\-\ titers\\:\\ 0\\.04455534932233588\ \(0\)\
\-\ evolve\\:\\ 0\\.04455534932233588\ \(0\)\
\-\ study\\:\\ 0\\.044498953954753714\ \(0\)\
\-\ preliminary\\:\\ 0\\.04393916369969254\ \(0\)\
\-\ frame\\:\\ 0\\.04393916369969254\ \(0\)\
\-\ preceding\\:\\ 0\\.04393916369969254\ \(0\)\
\-\ 34\\:\\ 0\\.043612462206441306\ \(0\)\
\-\ vaccination\\:\\ 0\\.04338175600174897\ \(0\)\
\-\ 20\\:\\ 0\\.043045079788213814\ \(0\)\
\-\ phase\\:\\ 0\\.042820418007258144\ \(0\)\
\-\ mri\\:\\ 0\\.04281162381049758\ \(0\)\
\-\ clinical\\:\\ 0\\.04228544543783948\ \(0\)\
\-\ days\\:\\ 0\\.04223809027777511\ \(0\)\
\-\ diffusion\\:\\ 0\\.042152290075248865\ \(0\)\
\-\ some\\:\\ 0\\.04198100941143783\ \(0\)\
\-\ rheumatology\\:\\ 0\\.04197135485469817\ \(0\)\
\-\ represent\\:\\ 0\\.04164112424796127\ \(0\)\
\-\ t1\\:\\ 0\\.041572150787910926\ \(0\)\
\-\ strep\\:\\ 0\\.04119041596318789\ \(0\)\
\-\ multiple\\:\\ 0\\.04079415003440083\ \(0\)\
\-\ rigidity\\:\\ 0\\.040501579042548155\ \(0\)\
\-\ after\\:\\ 0\\.04046009066237069\ \(0\)\
\-\ etiology\\:\\ 0\\.04031251012793026\ \(0\)\
\-\ involved\\:\\ 0\\.0401248552417223\ \(0\)\
\-\ this\\:\\ 0\\.04012221061461336\ \(0\)\
\-\ ed\\:\\ 0\\.04003251195306112\ \(0\)\
\-\ weeks\\:\\ 0\\.03998797231451426\ \(0\)\
\-\ ten\\:\\ 0\\.03988539341990482\ \(0\)\
\-\ there\\:\\ 0\\.03982288310867546\ \(0\)\
\-\ all\\:\\ 0\\.03971818453920417\ \(0\)\
\-\ two\\:\\ 0\\.03962332020283564\ \(0\)\
\-\ perivascular\\:\\ 0\\.03960005125448444\ \(0\)\
\-\ not\\:\\ 0\\.03951055437068952\ \(0\)\
\-\ ambulation\\:\\ 0\\.03932798572196125\ \(0\)\
\-\ considered\\:\\ 0\\.03899415477991392\ \(0\)\
\-\ deep\\:\\ 0\\.038953446904456894\ \(0\)\
\-\ been\\:\\ 0\\.03887315691862712\ \(0\)\
\-\ demyelination\\:\\ 0\\.03881911236297416\ \(0\)\
\-\ begin\\:\\ 0\\.03858037087662175\ \(0\)\
\-\ images\\:\\ 0\\.038579371670746924\ \(0\)\
\-\ tumefactive\\:\\ 0\\.03791758457491044\ \(0\)\
\-\ patients\\:\\ 0\\.037534932384756116\ \(0\)\
\-\ commonly\\:\\ 0\\.03702846426387232\ \(0\)\
\-\ studies\\:\\ 0\\.03670826333858336\ \(0\)\
\-\ more\\:\\ 0\\.0366376689867409\ \(0\)\
\-\ demyelinating\\:\\ 0\\.03661256203162737\ \(0\)\
\-\ abnormalities\\:\\ 0\\.03624886354026573\ \(0\)\
\-\ subcortical\\:\\ 0\\.035979690650790916\ \(0\)\
\-\ very\\:\\ 0\\.03589791548542627\ \(0\)\
\-\ confusion\\:\\ 0\\.03568721199360086\ \(0\)\
\-\ intensity\\:\\ 0\\.03553292553589085\ \(0\)\
\-\ by\\:\\ 0\\.03541768805554204\ \(0\)\
\-\ neurology\\:\\ 0\\.035274215442173525\ \(0\)\
\-\ mostly\\:\\ 0\\.03488846987896776\ \(0\)\
\-\ parents\\:\\ 0\\.03476534208318644\ \(0\)\
\-\ cr\\:\\ 0\\.034526600596834024\ \(0\)\
\-\ might\\:\\ 0\\.03407650516254671\ \(0\)\
\-\ less\\:\\ 0\\.034044199822040724\ \(0\)\
\-\ childhood\\:\\ 0\\.033760300897647165\ \(0\)\
\-\ brainstem\\:\\ 0\\.03365858782472932\ \(0\)\
\-\ cases\\:\\ 0\\.03365828239833287\ \(0\)\
\-\ exam\\:\\ 0\\.03358802988100336\ \(0\)\
\-\ affecting\\:\\ 0\\.03355861352223593\ \(0\)\
\-\ central\\:\\ 0\\.03341732381531464\ \(0\)\
\-\ had\\:\\ 0\\.03324349384096505\ \(0\)\
\-\ touch\\:\\ 0\\.032728321137166026\ \(0\)\
\-\ 99\\:\\ 0\\.032728321137166026\ \(0\)\
\-\ area\\:\\ 0\\.03241774422012143\ \(0\)\
\-\ glucose\\:\\ 0\\.0322337995750243\ \(0\)\
\-\ onset\\:\\ 0\\.03213320474448228\ \(0\)\
\-\ reduced\\:\\ 0\\.032001384053896076\ \(0\)\
\-\ an\\:\\ 0\\.031892970597006264\ \(0\)\
\-\ subacute\\:\\ 0\\.031220445162385802\ \(0\)\
\-\ rapid\\:\\ 0\\.03102439258293947\ \(0\)\
\-\ analysis\\:\\ 0\\.03102439258293947\ \(0\)\
\-\ protein\\:\\ 0\\.030960475506521003\ \(0\)\
\-\ infection\\:\\ 0\\.03022808911363148\ \(0\)\
\-\ erythema\\:\\ 0\\.03018748815162592\ \(0\)\
\-\ five\\:\\ 0\\.03013205309885458\ \(0\)\
\-\ focal\\:\\ 0\\.0299326897761191\ \(0\)\
\-\ likely\\:\\ 0\\.02990368964584356\ \(0\)\
\-\ enhance\\:\\ 0\\.02986249597481057\ \(0\)\
\-\ time\\:\\ 0\\.029660984118309787\ \(0\)\
\-\ appropriate\\:\\ 0\\.029309880046311264\ \(0\)\
\-\ blood\\:\\ 0\\.029062315632412065\ \(0\)\
\-\ received\\:\\ 0\\.029029105123824728\ \(0\)\
\-\ unable\\:\\ 0\\.028893615953530908\ \(0\)\
\-\ subtle\\:\\ 0\\.028761194727731778\ \(0\)\
\-\ therapy\\:\\ 0\\.02875220859553868\ \(0\)\
\-\ gray\\:\\ 0\\.0285469453381721\ \(0\)\
\-\ high\\:\\ 0\\.028440429818224557\ \(0\)\
\-\ flair\\:\\ 0\\.028381023450202554\ \(0\)\
\-\ mild\\:\\ 0\\.028367223289756088\ \(0\)\
\-\ signal\\:\\ 0\\.028367223289756088\ \(0\)\
\-\ disorder\\:\\ 0\\.028219679306631544\ \(0\)\
\-\ difficulty\\:\\ 0\\.028062667076988183\ \(0\)\
\-\ admission\\:\\ 0\\.02783478028815904\ \(0\)\
\-\ over\\:\\ 0\\.027825391446053324\ \(0\)\
\-\ 23\\:\\ 0\\.027508781423282072\ \(0\)\
\-\ affected\\:\\ 0\\.027438740415121267\ \(0\)\
\-\ bone\\:\\ 0\\.027304317290428558\ \(0\)\
\-\ foci\\:\\ 0\\.027267222131874155\ \(0\)\
\-\ resolution\\:\\ 0\\.027067827105058482\ \(0\)\
\-\ eye\\:\\ 0\\.026688341302040747\ \(0\)\
\-\ glassy\\:\\ 0\\.026675863401275528\ \(0\)\
\-\ nomral\\:\\ 0\\.026675863401275528\ \(0\)\
\-\ edmea\\:\\ 0\\.026675863401275528\ \(0\)\
\-\ hypersensative\\:\\ 0\\.026675863401275528\ \(0\)\
\-\ sandpaper\\:\\ 0\\.026675863401275528\ \(0\)\
\-\ 654\\:\\ 0\\.026675863401275528\ \(0\)\
\-\ ibili\\:\\ 0\\.026675863401275528\ \(0\)\
\-\ ferretin\\:\\ 0\\.026675863401275528\ \(0\)\
\-\ borrelia\\:\\ 0\\.026675863401275528\ \(0\)\
\-\ panel2\\:\\ 0\\.026675863401275528\ \(0\)\
\-\ opthamology\\:\\ 0\\.026675863401275528\ \(0\)\
\-\ catherizations\\:\\ 0\\.026675863401275528\ \(0\)\
\-\ acyclrovir\\:\\ 0\\.026675863401275528\ \(0\)\
\-\ jia\\:\\ 0\\.026675863401275528\ \(0\)\
\-\ ddischarged\\:\\ 0\\.026675863401275528\ \(0\)\
\-\ drifting\\:\\ 0\\.026675863401275528\ \(0\)\
\-\ meylitis\\:\\ 0\\.026675863401275528\ \(0\)\
\-\ expertise\\:\\ 0\\.026675863401275528\ \(0\)\
\-\ cntr\\:\\ 0\\.026675863401275528\ \(0\)\
\-\ sel\\:\\ 0\\.026675863401275528\ \(0\)\
\-\ panencephalitis\\:\\ 0\\.026675863401275528\ \(0\)\
\-\ aidp\\:\\ 0\\.026675863401275528\ \(0\)\
\-\ presentsto\\:\\ 0\\.026675863401275528\ \(0\)\
\-\ myelopathies\\:\\ 0\\.026675863401275528\ \(0\)\
\-\ anisotropy\\:\\ 0\\.026675863401275528\ \(0\)\
\-\ paainfectious\\:\\ 0\\.026675863401275528\ \(0\)\
\-\ astrocytosis\\:\\ 0\\.026675863401275528\ \(0\)\
\-\ nonhemorrhagic\\:\\ 0\\.026675863401275528\ \(0\)\
\-\ limited\\:\\ 0\\.02662742039409629\ \(0\)\
\-\ presenting\\:\\ 0\\.026133717871838203\ \(0\)\
\-\ present\\:\\ 0\\.025678027287645067\ \(0\)\
\-\ history\\:\\ 0\\.02549177413519192\ \(0\)\
\-\ calm\\:\\ 0\\.025490211601168666\ \(0\)\
\-\ tonsilar\\:\\ 0\\.025490211601168666\ \(0\)\
\-\ strawberry\\:\\ 0\\.025490211601168666\ \(0\)\
\-\ 2sec\\:\\ 0\\.025490211601168666\ \(0\)\
\-\ cooperation\\:\\ 0\\.025490211601168666\ \(0\)\
\-\ anc\\:\\ 0\\.025490211601168666\ \(0\)\
\-\ tprotein\\:\\ 0\\.025490211601168666\ \(0\)\
\-\ burgdorferi\\:\\ 0\\.025490211601168666\ \(0\)\
\-\ aso\\:\\ 0\\.025490211601168666\ \(0\)\
\-\ reconsidered\\:\\ 0\\.025490211601168666\ \(0\)\
\-\ leukoencephalitis\\:\\ 0\\.025490211601168666\ \(0\)\
\-\ catheterizations\\:\\ 0\\.025490211601168666\ \(0\)\
\-\ everything\\:\\ 0\\.025490211601168666\ \(0\)\
\-\ perivenular\\:\\ 0\\.025490211601168666\ \(0\)\
\-\ worsening\\:\\ 0\\.025475906776109242\ \(0\)\
\-\ process\\:\\ 0\\.02502120452450648\ \(0\)\
\-\ malignancy\\:\\ 0\\.024975334844037005\ \(0\)\
\-\ but\\:\\ 0\\.024745704349293015\ \(0\)\
\-\ distressed\\:\\ 0\\.024648978261381665\ \(0\)\
\-\ smiling\\:\\ 0\\.024648978261381665\ \(0\)\
\-\ derm\\:\\ 0\\.024648978261381665\ \(0\)\
\-\ 245\\:\\ 0\\.024648978261381665\ \(0\)\
\-\ triglyceride\\:\\ 0\\.024648978261381665\ \(0\)\
\-\ banding\\:\\ 0\\.024648978261381665\ \(0\)\
\-\ cow\\:\\ 0\\.024648978261381665\ \(0\)\
\-\ tensor\\:\\ 0\\.024648978261381665\ \(0\)\
\-\ management\\:\\ 0\\.02464232150168362\ \(0\)\
\-\ course\\:\\ 0\\.02464232150168362\ \(0\)\
\-\ hospital\\:\\ 0\\.02464232150168362\ \(0\)\
\-\ contrast\\:\\ 0\\.024314245713377366\ \(0\)\
\-\ involvement\\:\\ 0\\.024146050419377414\ \(0\)\
\-\ reported\\:\\ 0\\.024028294341614905\ \(0\)\
\-\ tms\\:\\ 0\\.023996466989740135\ \(0\)\
\-\ labia\\:\\ 0\\.023996466989740135\ \(0\)\
\-\ enterococcus\\:\\ 0\\.023996466989740135\ \(0\)\
\-\ 305\\:\\ 0\\.023996466989740135\ \(0\)\
\-\ weakly\\:\\ 0\\.023996466989740135\ \(0\)\
\-\ nuc\\:\\ 0\\.023996466989740135\ \(0\)\
\-\ averaging\\:\\ 0\\.023996466989740135\ \(0\)\
\-\ mononuclear\\:\\ 0\\.023996466989740135\ \(0\)\
\-\ cortical\\:\\ 0\\.02395108722324047\ \(0\)\
\-\ otherwise\\:\\ 0\\.02378101000837132\ \(0\)\
\-\ identified\\:\\ 0\\.023652064690694256\ \(0\)\
\-\ wbc\\:\\ 0\\.02357963832507533\ \(0\)\
\-\ dbili\\:\\ 0\\.023463326461274806\ \(0\)\
\-\ abs\\:\\ 0\\.023463326461274806\ \(0\)\
\-\ synthesis\\:\\ 0\\.023463326461274806\ \(0\)\
\-\ rocephin\\:\\ 0\\.023463326461274806\ \(0\)\
\-\ neuromyelitis\\:\\ 0\\.023463326461274806\ \(0\)\
\-\ optica\\:\\ 0\\.023463326461274806\ \(0\)\
\-\ devic\\:\\ 0\\.023463326461274806\ \(0\)\
\-\ meningismus\\:\\ 0\\.023463326461274806\ \(0\)\
\-\ illustrate\\:\\ 0\\.023463326461274806\ \(0\)\
\-\ oncologic\\:\\ 0\\.023463326461274806\ \(0\)\
\-\ lips\\:\\ 0\\.023012562567242944\ \(0\)\
\-\ cool\\:\\ 0\\.023012562567242944\ \(0\)\
\-\ segs\\:\\ 0\\.023012562567242944\ \(0\)\
\-\ fibrinogen\\:\\ 0\\.023012562567242944\ \(0\)\
\-\ rheumatologic\\:\\ 0\\.023012562567242944\ \(0\)\
\-\ rheumatologist\\:\\ 0\\.023012562567242944\ \(0\)\
\-\ pml\\:\\ 0\\.023012562567242944\ \(0\)\
\-\ occurrences\\:\\ 0\\.023012562567242944\ \(0\)\
\-\ hurt\\:\\ 0\\.023012562567242944\ \(0\)\
\-\ presentation\\:\\ 0\\.022965252472958445\ \(0\)\
\-\ which\\:\\ 0\\.022754463940927887\ \(0\)\
\-\ masses\\:\\ 0\\.02271162555297063\ \(0\)\
\-\ areas\\:\\ 0\\.022649900924292758\ \(0\)\
\-\ conjunctivitis\\:\\ 0\\.02262209312148781\ \(0\)\
\-\ 199\\:\\ 0\\.02262209312148781\ \(0\)\
\-\ readmitted\\:\\ 0\\.02262209312148781\ \(0\)\
\-\ yesterday\\:\\ 0\\.02262209312148781\ \(0\)\
\-\ angio\\:\\ 0\\.02262209312148781\ \(0\)\
\-\ possible\\:\\ 0\\.022604031243823274\ \(0\)\
\-\ inflammatory\\:\\ 0\\.0225585185294649\ \(0\)\
\-\ week\\:\\ 0\\.022438854932221912\ \(0\)\
\-\ neutrophil\\:\\ 0\\.02227767466116794\ \(0\)\
\-\ 155\\:\\ 0\\.02227767466116794\ \(0\)\
\-\ empirically\\:\\ 0\\.02227767466116794\ \(0\)\
\-\ refered\\:\\ 0\\.02227767466116794\ \(0\)\
\-\ complexes\\:\\ 0\\.02227767466116794\ \(0\)\
\-\ bilaterally\\:\\ 0\\.022249476977376857\ \(0\)\
\-\ vascular\\:\\ 0\\.022024512539279135\ \(0\)\
\-\ positive\\:\\ 0\\.021983278378246093\ \(0\)\
\-\ responds\\:\\ 0\\.02196958184984627\ \(0\)\
\-\ myelin\\:\\ 0\\.02196958184984627\ \(0\)\
\-\ bilat\\:\\ 0\\.02196958184984627\ \(0\)\
\-\ expressed\\:\\ 0\\.02196958184984627\ \(0\)\
\-\ nuchal\\:\\ 0\\.02196958184984627\ \(0\)\
\-\ body\\:\\ 0\\.021955949570201104\ \(0\)\
\-\ out\\:\\ 0\\.021928747873350585\ \(0\)\
\-\ several\\:\\ 0\\.02188818109141786\ \(0\)\
\-\ further\\:\\ 0\\.021728670632655107\ \(0\)\
\-\ cath\\:\\ 0\\.021690878000874485\ \(0\)\
\-\ titer\\:\\ 0\\.021690878000874485\ \(0\)\
\-\ oligoclonal\\:\\ 0\\.021690878000874485\ \(0\)\
\-\ delineated\\:\\ 0\\.021690878000874485\ \(0\)\
\-\ necessitating\\:\\ 0\\.021690878000874485\ \(0\)\
\-\ differential\\:\\ 0\\.021676452836831124\ \(0\)\
\-\ adjacent\\:\\ 0\\.02162469715145359\ \(0\)\
\-\ exudate\\:\\ 0\\.021436441321380943\ \(0\)\
\-\ rhinorrhea\\:\\ 0\\.021436441321380943\ \(0\)\
\-\ entry\\:\\ 0\\.021436441321380943\ \(0\)\
\-\ mono\\:\\ 0\\.021436441321380943\ \(0\)\
\-\ 135\\:\\ 0\\.021436441321380943\ \(0\)\
\-\ lymphocyte\\:\\ 0\\.021436441321380943\ \(0\)\
\-\ mycoplasma\\:\\ 0\\.021436441321380943\ \(0\)\
\-\ immunoglobulin\\:\\ 0\\.021436441321380943\ \(0\)\
\-\ acyclovir\\:\\ 0\\.021436441321380943\ \(0\)\
\-\ ache\\:\\ 0\\.021436441321380943\ \(0\)\
\-\ supplemental\\:\\ 0\\.021436441321380943\ \(0\)\
\-\ day\\:\\ 0\\.021250474361583716\ \(0\)\
\-\ hsm\\:\\ 0\\.021202382265396183\ \(0\)\
\-\ tanner\\:\\ 0\\.021202382265396183\ \(0\)\
\-\ ck\\:\\ 0\\.021202382265396183\ \(0\)\
\-\ uric\\:\\ 0\\.021202382265396183\ \(0\)\
\-\ pcr\\:\\ 0\\.021202382265396183\ \(0\)\
\-\ peduncle\\:\\ 0\\.021202382265396183\ \(0\)\
\-\ distinction\\:\\ 0\\.021202382265396183\ \(0\)\
\-\ medical\\:\\ 0\\.02120233948673582\ \(0\)\
\-\ usually\\:\\ 0\\.021002074154159694\ \(0\)\
\-\ vagina\\:\\ 0\\.020985677427349084\ \(0\)\
\-\ 153\\:\\ 0\\.020985677427349084\ \(0\)\
\-\ igm\\:\\ 0\\.020985677427349084\ \(0\)\
\-\ id\\:\\ 0\\.020985677427349084\ \(0\)\
\-\ peduncles\\:\\ 0\\.020985677427349084\ \(0\)\
\-\ relaxation\\:\\ 0\\.020985677427349084\ \(0\)\
\-\ insult\\:\\ 0\\.020985677427349084\ \(0\)\
\-\ diff\\:\\ 0\\.020783930049739406\ \(0\)\
\-\ gravity\\:\\ 0\\.020783930049739406\ \(0\)\
\-\ ebv\\:\\ 0\\.020783930049739406\ \(0\)\
\-\ breakdown\\:\\ 0\\.020783930049739406\ \(0\)\
\-\ thorough\\:\\ 0\\.020783930049739406\ \(0\)\
\-\ guide\\:\\ 0\\.020783930049739406\ \(0\)\
\-\ negative\\:\\ 0\\.02065365416815633\ \(0\)\
\-\ seem\\:\\ 0\\.020595207981593946\ \(0\)\
\-\ rpr\\:\\ 0\\.020595207981593946\ \(0\)\
\-\ hsv\\:\\ 0\\.020595207981593946\ \(0\)\
\-\ seemed\\:\\ 0\\.020595207981593946\ \(0\)\
\-\ myelopathy\\:\\ 0\\.020595207981593946\ \(0\)\
\-\ postcontrast\\:\\ 0\\.020595207981593946\ \(0\)\
\-\ perrl\\:\\ 0\\.02041793084837074\ \(0\)\
\-\ aspirate\\:\\ 0\\.02041793084837074\ \(0\)\
\-\ clonus\\:\\ 0\\.02041793084837074\ \(0\)\
\-\ ir\\:\\ 0\\.02041793084837074\ \(0\)\
\-\ clean\\:\\ 0\\.02041793084837074\ \(0\)\
\-\ multilevel\\:\\ 0\\.02041793084837074\ \(0\)\
\-\ hyperintensities\\:\\ 0\\.02041793084837074\ \(0\)\
\-\ platelet\\:\\ 0\\.020250789521274078\ \(0\)\
\-\ neuroimaging\\:\\ 0\\.020250789521274078\ \(0\)\
\-\ distinguishing\\:\\ 0\\.020250789521274078\ \(0\)\
\-\ changes\\:\\ 0\\.020162082298052494\ \(0\)\
\-\ appearance\\:\\ 0\\.0201121387470561\ \(0\)\
\-\ localize\\:\\ 0\\.020092687388824304\ \(0\)\
\-\ barrier\\:\\ 0\\.020092687388824304\ \(0\)\
\-\ polyneuropathy\\:\\ 0\\.020092687388824304\ \(0\)\
\-\ sclera\\:\\ 0\\.01994269670995241\ \(0\)\
\-\ rf\\:\\ 0\\.01994269670995241\ \(0\)\
\-\ vancomycin\\:\\ 0\\.01994269670995241\ \(0\)\
\-\ ecg\\:\\ 0\\.01980002562724222\ \(0\)\
\-\ presumptive\\:\\ 0\\.01980002562724222\ \(0\)\
\-\ scan\\:\\ 0\\.019792794426092098\ \(0\)\
\-\ however\\:\\ 0\\.019745894781975526\ \(0\)\
\-\ ana\\:\\ 0\\.01940955618148708\ \(0\)\
\-\ courses\\:\\ 0\\.01940955618148708\ \(0\)\
\-\ nervous\\:\\ 0\\.01940955618148708\ \(0\)\
\-\ if\\:\\ 0\\.0193836518150214\ \(0\)\
\-\ pale\\:\\ 0\\.019290185438310875\ \(0\)\
\-\ tbili\\:\\ 0\\.019290185438310875\ \(0\)\
\-\ progressing\\:\\ 0\\.019290185438310875\ \(0\)\
\-\ nd\\:\\ 0\\.01917549712550232\ \(0\)\
\-\ gu\\:\\ 0\\.01917549712550232\ \(0\)\
\-\ ph\\:\\ 0\\.01917549712550232\ \(0\)\
\-\ paresthesias\\:\\ 0\\.01917549712550232\ \(0\)\
\-\ occurrence\\:\\ 0\\.01917549712550232\ \(0\)\
\-\ one\\:\\ 0\\.019100819134419418\ \(0\)\
\-\ pulm\\:\\ 0\\.019065137721167216\ \(0\)\
\-\ pink\\:\\ 0\\.019065137721167216\ \(0\)\
\-\ profile\\:\\ 0\\.019065137721167216\ \(0\)\
\-\ acutely\\:\\ 0\\.019065137721167216\ \(0\)\
\-\ impaired\\:\\ 0\\.01895879228745522\ \(0\)\
\-\ than\\:\\ 0\\.018911482193170723\ \(0\)\
\-\ at\\:\\ 0\\.018901387803986376\ \(0\)\
\-\ check\\:\\ 0\\.01885617905225852\ \(0\)\
\-\ school\\:\\ 0\\.01885617905225852\ \(0\)\
\-\ sharply\\:\\ 0\\.01885617905225852\ \(0\)\
\-\ permanent\\:\\ 0\\.01885617905225852\ \(0\)\
\-\ basic\\:\\ 0\\.018757044909845547\ \(0\)\
\-\ raised\\:\\ 0\\.018757044909845547\ \(0\)\
\-\ cmv\\:\\ 0\\.01866116165952924\ \(0\)\
\-\ stopped\\:\\ 0\\.01866116165952924\ \(0\)\
\-\ pronounced\\:\\ 0\\.01866116165952924\ \(0\)\
\-\ wt\\:\\ 0\\.018568322841700083\ \(0\)\
\-\ co2\\:\\ 0\\.018568322841700083\ \(0\)\
\-\ mellitus\\:\\ 0\\.018568322841700083\ \(0\)\
\-\ neuritis\\:\\ 0\\.018568322841700083\ \(0\)\
\-\ mimic\\:\\ 0\\.018568322841700083\ \(0\)\
\-\ consisting\\:\\ 0\\.018568322841700083\ \(0\)\
\-\ coma\\:\\ 0\\.018568322841700083\ \(0\)\
\-\ cl\\:\\ 0\\.01847834106087376\ \(0\)\
\-\ regimen\\:\\ 0\\.01847834106087376\ \(0\)\
\-\ predominance\\:\\ 0\\.01847834106087376\ \(0\)\
\-\ hospitalization\\:\\ 0\\.018391045708476876\ \(0\)\
\-\ pineal\\:\\ 0\\.018391045708476876\ \(0\)\
\-\ pounds\\:\\ 0\\.018391045708476876\ \(0\)\
\-\ infiltrates\\:\\ 0\\.018391045708476876\ \(0\)\
\-\ nuclei\\:\\ 0\\.018391045708476876\ \(0\)\
\-\ correlate\\:\\ 0\\.018391045708476876\ \(0\)\
\-\ ctab\\:\\ 0\\.018306281015813684\ \(0\)\
\-\ urology\\:\\ 0\\.018306281015813684\ \(0\)\
\-\ abrupt\\:\\ 0\\.018306281015813684\ \(0\)\
\-\ supple\\:\\ 0\\.018223904381380218\ \(0\)\
\-\ opening\\:\\ 0\\.018223904381380218\ \(0\)\
\-\ provider\\:\\ 0\\.018223904381380218\ \(0\)\
\-\ lesser\\:\\ 0\\.018223904381380218\ \(0\)\
\-\ eomi\\:\\ 0\\.01814378492740601\ \(0\)\
\-\ ldh\\:\\ 0\\.01814378492740601\ \(0\)\
\-\ constipation\\:\\ 0\\.01814378492740601\ \(0\)\
\-\ ingestion\\:\\ 0\\.018065802248930445\ \(0\)\
\-\ tongue\\:\\ 0\\.017989845325395458\ \(0\)\
\-\ rash\\:\\ 0\\.017989845325395458\ \(0\)\
\-\ neg\\:\\ 0\\.017989845325395458\ \(0\)\
\-\ suggestion\\:\\ 0\\.017989845325395458\ \(0\)\
\-\ bilateral\\:\\ 0\\.01792950809845837\ \(0\)\
\-\ pain\\:\\ 0\\.017906765841826683\ \(0\)\
\-\ crp\\:\\ 0\\.01784360599680043\ \(0\)\
\-\ specimen\\:\\ 0\\.017773140487348356\ \(0\)\
\-\ techniques\\:\\ 0\\.017773140487348356\ \(0\)\
\-\ impairment\\:\\ 0\\.017773140487348356\ \(0\)\
\-\ 92\\:\\ 0\\.0177043331447339\ \(0\)\
\-\ amylase\\:\\ 0\\.0177043331447339\ \(0\)\
\-\ sle\\:\\ 0\\.0177043331447339\ \(0\)\
\-\ column\\:\\ 0\\.0177043331447339\ \(0\)\
\-\ preferred\\:\\ 0\\.0177043331447339\ \(0\)\
\-\ whereas\\:\\ 0\\.0177043331447339\ \(0\)\
\-\ noted\\:\\ 0\\.01768802797741318\ \(0\)\
\-\ diagnoses\\:\\ 0\\.017637107721086762\ \(0\)\
\-\ resolve\\:\\ 0\\.017637107721086762\ \(0\)\
\-\ lipase\\:\\ 0\\.01757139310973868\ \(0\)\
\-\ consult\\:\\ 0\\.01757139310973868\ \(0\)\
\-\ sclerosing\\:\\ 0\\.01757139310973868\ \(0\)\
\-\ marginated\\:\\ 0\\.01757139310973868\ \(0\)\
\-\ others\\:\\ 0\\.01757139310973868\ \(0\)\
\-\ panel\\:\\ 0\\.017507122893154363\ \(0\)\
\-\ potentially\\:\\ 0\\.017507122893154363\ \(0\)\
\-\ fairly\\:\\ 0\\.017507122893154363\ \(0\)\
\-\ whole\\:\\ 0\\.017507122893154363\ \(0\)\
\-\ alk\\:\\ 0\\.01744423493948388\ \(0\)\
\-\ strong\\:\\ 0\\.01738267104159322\ \(0\)\
\-\ average\\:\\ 0\\.01738267104159322\ \(0\)\
\-\ most\\:\\ 0\\.017362147870089852\ \(0\)\
\-\ acid\\:\\ 0\\.017322376593316497\ \(0\)\
\-\ repeated\\:\\ 0\\.017322376593316497\ \(0\)\
\-\ receiving\\:\\ 0\\.017322376593316497\ \(0\)\
\-\ phos\\:\\ 0\\.017263300298417012\ \(0\)\
\-\ index\\:\\ 0\\.017263300298417012\ \(0\)\
\-\ completed\\:\\ 0\\.017263300298417012\ \(0\)\
\-\ were\\:\\ 0\\.01719670408179599\ \(0\)\
\-\ sulci\\:\\ 0\\.01714861198560846\ \(0\)\
\-\ oxygen\\:\\ 0\\.01714861198560846\ \(0\)\
\-\ surrounded\\:\\ 0\\.01714861198560846\ \(0\)\
\-\ periventricular\\:\\ 0\\.01714861198560846\ \(0\)\
\-\ extremely\\:\\ 0\\.01709291168932115\ \(0\)\
\-\ presumed\\:\\ 0\\.017038252581273356\ \(0\)\
\-\ ages\\:\\ 0\\.017038252581273356\ \(0\)\
\-\ fine\\:\\ 0\\.01698459644944523\ \(0\)\
\-\ questionable\\:\\ 0\\.01698459644944523\ \(0\)\
\-\ collagen\\:\\ 0\\.01693190714756136\ \(0\)\
\-\ band\\:\\ 0\\.016880150448823582\ \(0\)\
\-\ floor\\:\\ 0\\.016880150448823582\ \(0\)\
\-\ edge\\:\\ 0\\.01682929391236466\ \(0\)\
\-\ consideration\\:\\ 0\\.01682929391236466\ \(0\)\
\-\ moderately\\:\\ 0\\.01682929391236466\ \(0\)\
\-\ rbc\\:\\ 0\\.016779306761117965\ \(0\)\
\-\ evaluating\\:\\ 0\\.016779306761117965\ \(0\)\
\-\ throat\\:\\ 0\\.016730159769951684\ \(0\)\
\-\ rapidly\\:\\ 0\\.016681825163049495\ \(0\)\
\-\ water\\:\\ 0\\.016681825163049495\ \(0\)\
\-\ cv\\:\\ 0\\.016587488687241494\ \(0\)\
\-\ tone\\:\\ 0\\.016541437701806223\ \(0\)\
\-\ hiv\\:\\ 0\\.016496100713966923\ \(0\)\
\-\ mra\\:\\ 0\\.016496100713966923\ \(0\)\
\-\ findings\\:\\ 0\\.016465061083287106\ \(0\)\
\-\ gen\\:\\ 0\\.0164514559209799\ \(0\)\
\-\ remarkable\\:\\ 0\\.0164514559209799\ \(0\)\
\-\ sensitive\\:\\ 0\\.016407482503759747\ \(0\)\
\-\ disk\\:\\ 0\\.016407482503759747\ \(0\)\
\-\ recovery\\:\\ 0\\.016407482503759747\ \(0\)\
\-\ services\\:\\ 0\\.016364160568583013\ \(0\)\
\-\ final\\:\\ 0\\.016364160568583013\ \(0\)\
\-\ death\\:\\ 0\\.016364160568583013\ \(0\)\
\-\ reference\\:\\ 0\\.016321471093047497\ \(0\)\
\-\ infarcts\\:\\ 0\\.016321471093047497\ \(0\)\
\-\ patchy\\:\\ 0\\.016237917490540273\ \(0\)\
\-\ hemispheres\\:\\ 0\\.01619701924148636\ \(0\)\
\-\ make\\:\\ 0\\.01619701924148636\ \(0\)\
\-\ differentiation\\:\\ 0\\.01619701924148636\ \(0\)\
\-\ improve\\:\\ 0\\.01619701924148636\ \(0\)\
\-\ prolonged\\:\\ 0\\.016156685124225408\ \(0\)\
\-\ straight\\:\\ 0\\.01611689978751215\ \(0\)\
\-\ female\\:\\ 0\\.016098289129299927\ \(0\)\
\-\ bun\\:\\ 0\\.01607764849831015\ \(0\)\
\-\ alt\\:\\ 0\\.016038917109036585\ \(0\)\
\-\ ast\\:\\ 0\\.016000692026948038\ \(0\)\
\-\ concerning\\:\\ 0\\.016000692026948038\ \(0\)\
\-\ lesion\\:\\ 0\\.015994073015779122\ \(0\)\
\-\ developing\\:\\ 0\\.0159629601855016\ \(0\)\
\-\ ua\\:\\ 0\\.015925709017540216\ \(0\)\
\-\ differentiated\\:\\ 0\\.015925709017540216\ \(0\)\
\-\ group\\:\\ 0\\.01585260078116649\ \(0\)\
\-\ murmur\\:\\ 0\\.01581672085690657\ \(0\)\
\-\ pulses\\:\\ 0\\.01581672085690657\ \(0\)\
\-\ na\\:\\ 0\\.01581672085690657\ \(0\)\
\-\ choice\\:\\ 0\\.01581672085690657\ \(0\)\
\-\ helpful\\:\\ 0\\.01581672085690657\ \(0\)\
\-\ cultures\\:\\ 0\\.01571164929694148\ \(0\)\
\-\ half\\:\\ 0\\.01571164929694148\ \(0\)\
\-\ once\\:\\ 0\\.015677448004840038\ \(0\)\
\-\ returned\\:\\ 0\\.015677448004840038\ \(0\)\
\-\ nonspecific\\:\\ 0\\.015677448004840038\ \(0\)\
\-\ 66\\:\\ 0\\.0156436421122578\ \(0\)\
\-\ 43\\:\\ 0\\.015610222581192901\ \(0\)\
\-\ antibiotic\\:\\ 0\\.015610222581192901\ \(0\)\
\-\ sometimes\\:\\ 0\\.015610222581192901\ \(0\)\
\-\ bacterial\\:\\ 0\\.015610222581192901\ \(0\)\
\-\ dose\\:\\ 0\\.015577180680029709\ \(0\)\
\-\ consciousness\\:\\ 0\\.015577180680029709\ \(0\)\
\-\ adults\\:\\ 0\\.015577180680029709\ \(0\)\
\-\ rrr\\:\\ 0\\.015544507969844823\ \(0\)\
\-\ neuro\\:\\ 0\\.015544507969844823\ \(0\)\
\-\ abd\\:\\ 0\\.015512196291469734\ \(0\)\
\-\ echo\\:\\ 0\\.015448624719528513\ \(0\)\
\-\ adult\\:\\ 0\\.015386405837395046\ \(0\)\
\-\ response\\:\\ 0\\.015386405837395046\ \(0\)\
\-\ viral\\:\\ 0\\.015386405837395046\ \(0\)\
\-\ serial\\:\\ 0\\.015355785901699361\ \(0\)\
\-\ movement\\:\\ 0\\.015355785901699361\ \(0\)\
\-\ number\\:\\ 0\\.015355785901699361\ \(0\)\
\-\ rr\\:\\ 0\\.015325483276745645\ \(0\)\
\-\ characterized\\:\\ 0\\.015325483276745645\ \(0\)\
\-\ cerebellum\\:\\ 0\\.015325483276745645\ \(0\)\
\-\ occlusion\\:\\ 0\\.015325483276745645\ \(0\)\
\-\ esr\\:\\ 0\\.015265804120873035\ \(0\)\
\-\ extent\\:\\ 0\\.015265804120873035\ \(0\)\
\-\ has\\:\\ 0\\.015238397033009596\ \(0\)\
\-\ episodes\\:\\ 0\\.015236415158523151\ \(0\)\
\-\ leukemia\\:\\ 0\\.015236415158523151\ \(0\)\
\-\ conditions\\:\\ 0\\.015236415158523151\ \(0\)\
\-\ normally\\:\\ 0\\.015207318628509107\ \(0\)\
\-\ drug\\:\\ 0\\.015178508768476151\ \(0\)\
\-\ epidural\\:\\ 0\\.015149979984729257\ \(0\)\
\-\ higher\\:\\ 0\\.015149979984729257\ \(0\)\
\-\ poorly\\:\\ 0\\.01506602654942729\ \(0\)\
\-\ times\\:\\ 0\\.015011367441379493\ \(0\)\
\-\ asymmetric\\:\\ 0\\.015011367441379493\ \(0\)\
\-\ angiogram\\:\\ 0\\.01498441630921647\ \(0\)\
\-\ pediatric\\:\\ 0\\.014931247987405284\ \(0\)\
\-\ heent\\:\\ 0\\.014905022007667499\ \(0\)\
\-\ again\\:\\ 0\\.014879029150833313\ \(0\)\
\-\ systemic\\:\\ 0\\.014802408772470799\ \(0\)\
\-\ our\\:\\ 0\\.014777308385394733\ \(0\)\
\-\ fevers\\:\\ 0\\.01472774487444429\ \(0\)\
\-\ disorders\\:\\ 0\\.01472774487444429\ \(0\)\
\-\ involve\\:\\ 0\\.01467900746057958\ \(0\)\
\-\ felt\\:\\ 0\\.014654940023155632\ \(0\)\
\-\ volume\\:\\ 0\\.014654940023155632\ \(0\)\
\-\ able\\:\\ 0\\.014631069056799704\ \(0\)\
\-\ improvement\\:\\ 0\\.014560603547347634\ \(0\)\
\-\ reduction\\:\\ 0\\.014560603547347634\ \(0\)\
\-\ mental\\:\\ 0\\.014537487402147102\ \(0\)\
\-\ scans\\:\\ 0\\.014514552561912364\ \(0\)\
\-\ hemorrhagic\\:\\ 0\\.014469215574073064\ \(0\)\
\-\ problems\\:\\ 0\\.014469215574073064\ \(0\)\
\-\ 48\\:\\ 0\\.014446807976765454\ \(0\)\
\-\ complaint\\:\\ 0\\.014446807976765454\ \(0\)\
\-\ rest\\:\\ 0\\.014424570781086037\ \(0\)\
\-\ included\\:\\ 0\\.014424570781086037\ \(0\)\
\-\ optic\\:\\ 0\\.014358856169737958\ \(0\)\
\-\ incidence\\:\\ 0\\.014358856169737958\ \(0\)\
\-\ hr\\:\\ 0\\.014337275428689154\ \(0\)\
\-\ evident\\:\\ 0\\.014337275428689154\ \(0\)\
\-\ deficits\\:\\ 0\\.014337275428689154\ \(0\)\
\-\ discharged\\:\\ 0\\.014315852789726828\ \(0\)\
\-\ lack\\:\\ 0\\.01427347266908605\ \(0\)\
\-\ mother\\:\\ 0\\.014252510736025962\ \(0\)\
\-\ healthy\\:\\ 0\\.014149897500829263\ \(0\)\
\-\ generally\\:\\ 0\\.014129799984331547\ \(0\)\
\-\ poor\\:\\ 0\\.014070323144655084\ \(0\)\
\-\ started\\:\\ 0\\.014050763358416287\ \(0\)\
\-\ carotid\\:\\ 0\\.014050763358416287\ \(0\)\
\-\ herniation\\:\\ 0\\.014031333538494091\ \(0\)\
\-\ ventricular\\:\\ 0\\.014031333538494091\ \(0\)\
\-\ strength\\:\\ 0\\.013973806887054177\ \(0\)\
\-\ surface\\:\\ 0\\.01391739014407952\ \(0\)\
\-\ marrow\\:\\ 0\\.013862041290270825\ \(0\)\
\-\ clinically\\:\\ 0\\.013862041290270825\ \(0\)\
\-\ difficult\\:\\ 0\\.013843822059121774\ \(0\)\
\-\ recurrence\\:\\ 0\\.013772059509444504\ \(0\)\
\-\ segment\\:\\ 0\\.013772059509444504\ \(0\)\
\-\ growth\\:\\ 0\\.013754390711641036\ \(0\)\
\-\ young\\:\\ 0\\.013754390711641036\ \(0\)\
\-\ review\\:\\ 0\\.013736828033383218\ \(0\)\
\-\ frequently\\:\\ 0\\.013736828033383218\ \(0\)\
\-\ pending\\:\\ 0\\.013719370207560633\ \(0\)\
\-\ neurological\\:\\ 0\\.013702015989622975\ \(0\)\
\-\ total\\:\\ 0\\.013667613508822857\ \(0\)\
\-\ admitted\\:\\ 0\\.013667613508822857\ \(0\)\
\-\ continued\\:\\ 0\\.013667613508822857\ \(0\)\
\-\ children\\:\\ 0\\.013667613508822857\ \(0\)\
\-\ cerebellar\\:\\ 0\\.013650562864946177\ \(0\)\
\-\ another\\:\\ 0\\.013650562864946177\ \(0\)\
\-\ intermittent\\:\\ 0\\.013633611065937077\ \(0\)\
\-\ seizures\\:\\ 0\\.013616756972363935\ \(0\)\
\-\ suggestive\\:\\ 0\\.01358333744129904\ \(0\)\
\-\ good\\:\\ 0\\.01356676982111724\ \(0\)\
\-\ bp\\:\\ 0\\.013533913552529241\ \(0\)\
\-\ described\\:\\ 0\\.013533913552529241\ \(0\)\
\-\ function\\:\\ 0\\.013501422361146348\ \(0\)\
\-\ lymphadenopathy\\:\\ 0\\.013485311151575873\ \(0\)\
\-\ before\\:\\ 0\\.013485311151575873\ \(0\)\
\-\ inflammation\\:\\ 0\\.013406060308075831\ \(0\)\
\-\ general\\:\\ 0\\.013390464659696158\ \(0\)\
\-\ previously\\:\\ 0\\.013390464659696158\ \(0\)\
\-\ caused\\:\\ 0\\.013374951747240769\ \(0\)\
\-\ oral\\:\\ 0\\.013359520697501188\ \(0\)\
\-\ just\\:\\ 0\\.013344170651020374\ \(0\)\
\-\ sequences\\:\\ 0\\.013344170651020374\ \(0\)\
\-\ 90\\:\\ 0\\.013328900761805497\ \(0\)\
\-\ hepatic\\:\\ 0\\.013283563773966198\ \(0\)\
\-\ administration\\:\\ 0\\.013283563773966198\ \(0\)\
\-\ recommended\\:\\ 0\\.013268606313528775\ \(0\)\
\-\ hyperintense\\:\\ 0\\.013268606313528775\ \(0\)\
\-\ occurs\\:\\ 0\\.013151623628582288\ \(0\)\
\-\ many\\:\\ 0\\.013151623628582288\ \(0\)\
\-\ appear\\:\\ 0\\.013137324445371171\ \(0\)\
\-\ family\\:\\ 0\\.013123094844835393\ \(0\)\
\-\ upon\\:\\ 0\\.013123094844835393\ \(0\)\
\-\ where\\:\\ 0\\.013108934153046776\ \(0\)\
\-\ full\\:\\ 0\\.01303914140953343\ \(0\)\
\-\ results\\:\\ 0\\.012998051593304642\ \(0\)\
\-\ thin\\:\\ 0\\.012984482301485632\ \(0\)\
\-\ lymph\\:\\ 0\\.01297097568560279\ \(0\)\
\-\ bladder\\:\\ 0\\.012944148184224685\ \(0\)\
\-\ range\\:\\ 0\\.012944148184224685\ \(0\)\
\-\ motion\\:\\ 0\\.012930826169657504\ \(0\)\
\-\ typical\\:\\ 0\\.012891220456221413\ \(0\)\
\-\ made\\:\\ 0\\.012865111558309425\ \(0\)\
\-\ extensive\\:\\ 0\\.012852144010939452\ \(0\)\
\-\ enlargement\\:\\ 0\\.012788155086947313\ \(0\)\
\-\ progressive\\:\\ 0\\.01277552363257694\ \(0\)\
\-\ vs\\:\\ 0\\.012725536481330242\ \(0\)\
\-\ minimal\\:\\ 0\\.012725536481330242\ \(0\)\
\-\ system\\:\\ 0\\.012725536481330242\ \(0\)\
\-\ similar\\:\\ 0\\.012713172077539489\ \(0\)\
\-\ specific\\:\\ 0\\.012640063841165767\ \(0\)\
\-\ rate\\:\\ 0\\.012640063841165767\ \(0\)\
\-\ change\\:\\ 0\\.012640063841165767\ \(0\)\
\-\ unknown\\:\\ 0\\.012640063841165767\ \(0\)\
\-\ traumatic\\:\\ 0\\.012640063841165767\ \(0\)\
\-\ moderate\\:\\ 0\\.012522137492753318\ \(0\)\
\-\ second\\:\\ 0\\.012487667422018503\ \(0\)\
\-\ about\\:\\ 0\\.012487667422018503\ \(0\)\
\-\ used\\:\\ 0\\.012487667422018503\ \(0\)\
\-\ thoracic\\:\\ 0\\.012464911064839315\ \(0\)\
\-\ 14\\:\\ 0\\.012453598953479562\ \(0\)\
\-\ active\\:\\ 0\\.012386630137891892\ \(0\)\
\-\ referred\\:\\ 0\\.012342821421290772\ \(0\)\
\-\ vomiting\\:\\ 0\\.012342821421290772\ \(0\)\
\-\ antibiotics\\:\\ 0\\.012288967649832967\ \(0\)\
\-\ throughout\\:\\ 0\\.012267700813259775\ \(0\)\
\-\ occur\\:\\ 0\\.012267700813259775\ \(0\)\
\-\ tumors\\:\\ 0\\.012267700813259775\ \(0\)\
\-\ compression\\:\\ 0\\.012215200711152091\ \(0\)\
\-\ weakness\\:\\ 0\\.012173868897394323\ \(0\)\
\-\ could\\:\\ 0\\.01213311315557208\ \(0\)\
\-\ clear\\:\\ 0\\.012092917647897574\ \(0\)\
\-\ presence\\:\\ 0\\.011985146829248863\ \(0\)\
\-\ middle\\:\\ 0\\.011927994968206119\ \(0\)\
\-\ peripheral\\:\\ 0\\.011927994968206119\ \(0\)\
\-\ iv\\:\\ 0\\.011918577320324229\ \(0\)\
\-\ care\\:\\ 0\\.011918577320324229\ \(0\)\
\-\ required\\:\\ 0\\.011909189905713874\ \(0\)\
\-\ venous\\:\\ 0\\.011909189905713874\ \(0\)\
\-\ would\\:\\ 0\\.011807869696025654\ \(0\)\
\-\ obtained\\:\\ 0\\.011798830501378768\ \(0\)\
\-\ palpable\\:\\ 0\\.011718711047404561\ \(0\)\
\-\ girl\\:\\ 0\\.011701200952330489\ \(0\)\
\-\ effect\\:\\ 0\\.011701200952330489\ \(0\)\
\-\ complete\\:\\ 0\\.011692485067666774\ \(0\)\
\-\ hematoma\\:\\ 0\\.011675130849729114\ \(0\)\
\-\ 50\\:\\ 0\\.011649291119234332\ \(0\)\
\-\ weight\\:\\ 0\\.01163219061939005\ \(0\)\
\-\ labs\\:\\ 0\\.011556452301405179\ \(0\)\
\-\ new\\:\\ 0\\.011539884681223377\ \(0\)\
\-\ side\\:\\ 0\\.011523410400241987\ \(0\)\
\-\ headache\\:\\ 0\\.01149887170681724\ \(0\)\
\-\ given\\:\\ 0\\.011474537221252487\ \(0\)\
\-\ now\\:\\ 0\\.01145040357279615\ \(0\)\
\-\ neoplasm\\:\\ 0\\.011387004295053644\ \(0\)\
\-\ cause\\:\\ 0\\.011363579519802295\ \(0\)\
\-\ first\\:\\ 0\\.011256678634072339\ \(0\)\
\-\ palpation\\:\\ 0\\.011249190340249569\ \(0\)\
\-\ swelling\\:\\ 0\\.011226839832918431\ \(0\)\
\-\ type\\:\\ 0\\.011189964474897136\ \(0\)\
\-\ back\\:\\ 0\\.011124738488688429\ \(0\)\
\-\ right\\:\\ 0\\.011060598504117008\ \(0\)\
\-\ finding\\:\\ 0\\.010964373936675292\ \(0\)\
\-\ air\\:\\ 0\\.010910594450472013\ \(0\)\
\-\ should\\:\\ 0\\.01088407111997083\ \(0\)\
\-\ past\\:\\ 0\\.010857786204654357\ \(0\)\
\-\ between\\:\\ 0\\.010838226418415562\ \(0\)\
\-\ found\\:\\ 0\\.010793089381148311\ \(0\)\
\-\ any\\:\\ 0\\.010780320028368562\ \(0\)\
\-\ while\\:\\ 0\\.010780320028368562\ \(0\)\
\-\ such\\:\\ 0\\.010729793032355111\ \(0\)\
\-\ abscess\\:\\ 0\\.010711068248160762\ \(0\)\
\-\ bowel\\:\\ 0\\.010704853204078798\ \(0\)\
\-\ examination\\:\\ 0\\.010673974594656566\ \(0\)\
\-\ approximately\\:\\ 0\\.010643418651632802\ \(0\)\
\-\ age\\:\\ 0\\.010472227217046891\ \(0\)\
\-\ diffuse\\:\\ 0\\.01046078228212464\ \(0\)\
\-\ treated\\:\\ 0\\.010387462524383703\ \(0\)\
\-\ primary\\:\\ 0\\.010256751283048043\ \(0\)\
\-\ demonstrated\\:\\ 0\\.010251429758122108\ \(0\)\
\-\ neck\\:\\ 0\\.010203966868960692\ \(0\)\
\-\ loss\\:\\ 0\\.010162414807240044\ \(0\)\
\-\ syndrome\\:\\ 0\\.01005606937352805\ \(0\)\
\-\ head\\:\\ 0\\.009948658471726374\ \(0\)\
\-\ edema\\:\\ 0\\.009948658471726374\ \(0\)\
\-\ include\\:\\ 0\\.009924787505370446\ \(0\)\
\-\ secondary\\:\\ 0\\.009886994706103262\ \(0\)\
\-\ shows\\:\\ 0\\.009790051779334053\ \(0\)\
\-\ axial\\:\\ 0\\.009635297302819196\ \(0\)\
\-\ fluid\\:\\ 0\\.009630993877259894\ \(0\)\
\-\ significant\\:\\ 0\\.009630993877259894\ \(0\)\
\-\ cyst\\:\\ 0\\.009622405979340472\ \(0\)\
\-\ enhancement\\:\\ 0\\.009601045934475305\ \(0\)\
\-\ evidence\\:\\ 0\\.00946791673030291\ \(0\)\
\-\ common\\:\\ 0\\.009459794010802809\ \(0\)\
\-\ these\\:\\ 0\\.009419515451935246\ \(0\)\
\-\ abdominal\\:\\ 0\\.00912304641536733\ \(0\)\
\-\ consistent\\:\\ 0\\.009044588175873336\ \(0\)\
\-\ upper\\:\\ 0\\.008913838477245308\ \(0\)\
\-\ soft\\:\\ 0\\.008880380707896849\ \(0\)\
\-\ without\\:\\ 0\\.00879837373115173\ \(0\)\
\-\ demonstrate\\:\\ 0\\.008671766201542518\ \(0\)\
\-\ other\\:\\ 0\\.008662488000824285\ \(0\)\
\-\ small\\:\\ 0\\.00860439997922719\ \(0\)\
\-\ it\\:\\ 0\\.008538550833263376\ \(0\)\
\-\ lower\\:\\ 0\\.008523789685614435\ \(0\)\
\-\ demonstrates\\:\\ 0\\.008380137170728635\ \(0\)\
\-\ large\\:\\ 0\\.00835779377919656\ \(0\)\
\-\ treatment\\:\\ 0\\.00794584076925646\ \(0\)\
\-\ mass\\:\\ 0\\.0063715325918455015\ \(0\)\
\-\ ct\\:\\ 0\\.006350449752575488\ \(0\)\
\-\ left\\:\\ 0\\.005690106358410382\ \(0\)\
